Antibacterial Agents TRIZ Cases

Tyrosine kinase inhibitors target host cell pathways to block pathogen entry, reducing resistance development compared to direct antimicrobial strategies.

Beta-lactone compounds inhibit bacterial protease ClpP to reduce virulence without targeting viability, thereby minimizing drug resistance development.

Modified ezrin peptide activates MAPK/ERK pathway to overcome insufficient antiviral efficacy of existing HEP-1 treatments.

Controlled crystallization of romidepsin improves stability and bioavailability, resolving production efficiency trade-offs.

Novel small molecule compounds inhibit TNF-alpha production and cytokine release through targeted pathway modulation.

Novel heteroaryl substituted pyrazinyl-piperazine-piperidines act as potent CXCR3 antagonists to modulate receptor activity.

Isolated bacteriophage ΦCJ13 inhibits Enterotoxigenic E.coli growth while avoiding antibiotic resistance and drug residue issues in livestock.

A vaginal composition combines reactive oxygen species with a silicone polymer to treat bacterial vaginosis.

Tetravalent meningococcal conjugate vaccine utilizes outer membrane vesicle proteins from Neisseria meningitides group B serotypes as carrier components.

Solvent displacement replaces high-energy homogenization, reducing energy consumption while maintaining active ingredient integrity.

Colloidal silver composition stabilized with agar reduces toxicity and health risks while maintaining broad-spectrum antimicrobial activity.

Low molecular weight Pseudoalteromonas antarctica extract reduces sebum via MC5R inhibition while enhancing collagen synthesis and providing photoprotection.

Monoclonal antibodies targeting streptococcal M protein resolve safety issues of plasma-derived therapies while maintaining therapeutic efficacy.

Modified quinoline derivatives reduce treatment duration and improve compliance against multi-drug resistant tuberculosis strains.

Samarium(II) iodide mediates eight-membered ring formation, simplifying complex stereochemical control during pleuromutilin synthesis.

Novel hydantoin derivatives inhibit the bacterial LpxC enzyme to block Lipid A biosynthesis.

In-line nebulizer delivers amikacin and fosfomycin aerosol mist to treat ventilator-associated pneumonia with reduced airway irritation.

Antisense oligonucleotides bind natural antisense transcripts to form DNA-RNA hybrids, resolving specificity complexity trade-offs in NEU4 modulation.

Segmented CAR constructs enable marrow-infiltrating lymphocytes to target diverse tumor antigens beyond CD19, resolving applicability limits.

Avidin-biotin conjugates link co-stimulatory polypeptides to antigens, activating dendritic cells and T cells.

C-terminal C5a peptide analogs activate host innate immunity to overcome antibiotic resistance and biofilm barriers.

Multi-strain probiotics modulate immune responses to reduce allergic inflammation, avoiding side effects from conventional corticosteroid treatments.

Isolating VirB10 as a vaccine antigen reduces bacterial burden in hosts infected by Anaplasma phagocytophilum.

Novel peptidyl-ketoamide scaffolds resolve selectivity and potency trade-offs by forming reversible covalent bonds with rhomboid catalytic serines.

Novel quinolone compounds target Clostridium difficile to prevent relapse and reduce gut flora disruption from existing antibiotics.

A binding molecule targets the C2b domain of human complement factor C2 to inhibit activation through specific immunoglobulin variable regions.

A stable Mpa-Br peptide PEG conjugate activates the Tie2 receptor to stimulate angiogenesis and endothelial cell migration.

Fluorinated compounds inhibit the GmhA enzyme to block lipopolysaccharide formation, addressing insufficient cytosolic concentration of existing antibacterials.

A glycan composition alters gut microbial processing to enhance drug activity and therapeutic outcomes.

Spider silk particles loaded with water-soluble compounds eliminate toxic solvents and rapid resolubilization while enabling sustained release.

Specific compounds inhibit FosA enzymes, reversing bacterial resistance and restoring fosfomycin effectiveness against Gram-negative pathogens.

C-mannoside compounds inhibit FimH adhesin activity, reducing bacterial colonization and invasion without triggering antibiotic resistance.

Live Lawsonia intracellularis vaccine induces protective immunity while antibiotics abbreviate subclinical infection to prevent clinical disease.

Selected Lactobacillus fermentum strains reduce acetaldehyde concentration and counteract post-acidification to maintain pH stability during storage.

A multivalent pneumococcal conjugate composition uses mixed protein carriers to enhance antibody responses.

An extended release disulfiram suspension enables sustained therapeutic levels through controlled injection delivery.

Amino acid overlap at fusion junctions eliminates non-natural sequences, minimizing neo-epitope formation and immune response.

Small molecule compounds bind PD-L1 to block inhibitory interactions, restoring T cell activity against cancer and infectious diseases.

Small molecule inhibitors block BMP-induced SMAD phosphorylation, overcoming the specificity limits of traditional antibody-based approaches.

Cationic oligothioetheramides disrupt bacterial membranes to overcome antibiotic resistance while maintaining mammalian cell stability.

Polyethylene glycol derivative conjugates interleukin-12 to increase molecular weight and extend circulation half-life.

Cationic antiseptic compositions with hydrophobic phases enhance tissue substantivity.

Heterocyclidene acetamide derivatives act as TRPV1 receptor antagonists, resolving hERG channel inhibition and metabolic stability issues.

Blocking IL-25 receptor interactions reduces collagen production while preserving tissue repair mechanisms.

A hemostatic clamp fuses tissue via thermal energy to enable painless removal of redundant biological material.